Several small molecule HSP90 inhibitors including geldanamycin and its derivatives such as 17-AAG, which is in phase II clinical trials for cancer treatment, have been shown to reduce viral titers in cell culture models of vaccinia virus, influenza virus, vesicular stomatitis virus, several paramyxoviruses, La Crosse virus and hepatitis C virus [55]–[59]. Here, HSP90AA1 is linked to cancer.